Arkolith/Insider Trading/AKTS/Form 4

Segal Lloyd Mitchell

DirectorAktis Oncology, Inc. (AKTS) · full profile →Form 4 · filed Jan 12, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
1 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 12, 2026Conversion(C)20K——20K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 12, 2026Conversion(C)25K—$00
Jan 12, 2026Conversion(C)50K—$00

Transaction Codes

C
Conversion of a derivative

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-010575) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML